AVIR.US Atea Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
4.30 USD
Close of Nov 14, 2026
2.92 6.45
Market cap
USD 345M
P/E
-
P/B
1.93x
ROE
-83.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AVIR.US undervalued?

Graham number

The Graham number of Atea Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Atea Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Atea Pharmaceuticals Inc yet.

Atea Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Atea Pharmaceuticals Inc

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of c…

Full company profile